key: cord-0755256-2zjwbbiw
authors: Shafiek, Hala K.; El Lateef, Hanan M. Abd; Boraey, Naglaa F.; Nashat, Mohamed; Abd‐Elrehim, Ghada A. B.; Abouzeid, Heba; Hafez, Sahbaa F. M.; Shehata, Hassan; Elhewala, Ahmed A.; Abdel‐Aziz, Alsayed; Zeidan, Nancy M. S.; Soliman, Mohammed M.; Sallam, Mohammad M.; Nawara, Abdalla M.; Elgohary, Elsayed A.; Badr, Abdallah I.; Selim, Dalia M.; Razek, Suzan A.; Abdel Raouf, Batoul M.; Elmikaty, Hani A.; Ibrahim, Lamya M.; Shahin, Gehan H; Nabil, Rehab M.; Ibrahim, Mohamed A. M.; Salem, Hanan F.; Moustafa, Ahmed A. M.; Elshehawy, Naglaa A.; Abdel‐Aziz, Marwa M.; Eltrawy, Heba H.; Osman, Sherif F.; Fouad, Rania A.; Afify, Mona R.; Mohamed, Mohamed Y.; Yousif, Yousif M.; Yousef, Aly A.; Arafa, Mohamed A.
title: Cytokine profile in Egyptian children and adolescents with COVID‐19 pneumonia: A multicenter study
date: 2021-09-27
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.25679
sha: d282e8ee403834b830bc0a6249fc61db62bee702
doc_id: 755256
cord_uid: 2zjwbbiw

BACKGROUND: To date, the cytokine profile in children and adolescent with novel coronavirus disease 2019 (COVID‐19) has not been reported. OBJECTIVES: We investigated serum levels of a panel of key cytokines in children and adolescent with COVID‐19 pneumonia with a primary focus on “cytokine storm” cytokines such as interleukin (IL)‐1β, IL‐6, IL‐17, IL‐2, IL‐4, IL‐10, interferon (IFN‐γ), tumor necrosis factor (TNF)‐α, and two chemokines interferon‐inducible protein‐10 (IP‐10) and IL‐8. We also studied whether these cytokines could be potential markers for illness severity in COVID‐19 pneumonia. METHODS: Ninety‐two symptomatic patients aged less than 18 years with confirmed COVID‐19 pneumonia and 100 well‐matched healthy controls were included in this multi‐center study. For all patients, the presence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in respiratory fluid specimens was detected by real‐time reverse‐transcriptase polymerase chain reaction. We measured serum concentrations of studied cytokines by using flow cytometry. RESULTS: Patients with COVID‐19 had significantly higher median IL‐1β, IL‐6, IL‐8, IL‐10, IL‐17, TNF‐α, and IP‐10 serum levels than did control children (all p < 0.01). Patients with severe COVID‐19 pneumonia had significantly higher median IL‐1β, IL‐6, and IP‐10 serum levels as compared with those with moderate COVID‐19 pneumonia; all p < 0.01. ROC analysis revealed that three of the studied markers (IL‐6, IL‐1β, and IP‐10) could predict severe COVID‐19 pneumonia cases with the largest AUC for IL‐6 of 0.893 (95% confidence interval: 0.84–0.98; p < 0.01). CONCLUSION: Our study shows that pediatric patients with COVID‐19 pneumonia have markedly elevated serum IL‐1β, IL‐6, IL‐8, IL‐10, IL‐17, TNF‐α, and IP‐10 levels at the initial phase of the illness indicating a cytokine storm following SARS‐CoV‐2 infection. Moreover, serum IL‐6, IL‐1β, and IP‐10 concentrations were independent predictors for severe COVID‐19 pneumonia.

Results: Patients with COVID-19 had significantly higher median IL-1β, IL-6, IL-8, IL-10, IL-17, TNF-α, and IP-10 serum levels than did control children (all p < 0.01).

Patients with severe COVID-19 pneumonia had significantly higher median IL-1β, IL-6, and IP-10 serum levels as compared with those with moderate COVID-19 pneumonia; all p < 0.01. ROC analysis revealed that three of the studied markers (IL-6, IL-1β, and IP-10) could predict severe COVID-19 pneumonia cases with the largest AUC for IL-6 of 0.893 (95% confidence interval: 0.84-0.98; p < 0.01).

Conclusion: Our study shows that pediatric patients with COVID-19 pneumonia have markedly elevated serum IL-1β, IL-6, IL-8, IL-10, IL-17, TNF-α, and IP-10 levels at the initial phase of the illness indicating a cytokine storm following SARS-CoV-2 infection. Moreover, serum IL-6, IL-1β, and IP-10 concentrations were independent predictors for severe COVID-19 pneumonia. (SARS-CoV-2). 2 Children with COVID-19 may be asymptomatic or with mild clinical course compared with adults. 3 In the latest Italian study, very low case-fatality rates have been described in children and adolescents. 4 However, one of the most serious complications of COVID-19 is the development of pneumonia followed by acute respiratory distress syndrome (ARDS), sepsis, and multiple organ failure. 5 Cytokines are polypeptide signaling molecules that regulate many biological processes via cell surface receptors. 6 Key cytokines include pro-inflammatory cytokines e.g., (interleukin [IL]-1β, IL-6, IL-17, interferon [IFN]-γ, and tumor necrosis factor [TNF]-α); and anti-inflammatory cytokines (e.g., IL-10) and those involved in adaptive immunity such as IL-2 and IL-4. 7 In severe cases of SARS-CoV-2 infection, excessive levels of inflammatory cytokines have been described as cytokine storm contributes to an uncontrolled inflammatory immune response and widespread tissue damage. 8 The aberrant release of pro-inflammatory cytokines leads to pulmonary cell apoptosis which damages the alveolar and microvascular epithelial cell barrier, leading to alveolar edema and hypoxia in SARS patients. 9 Elevated IL-6 serum levels have been reported in adult patients with COVID-19 and were closely correlated to the severity of symptoms and the upcoming acute respiratory failure (ARF), thus may be of prognostic value in these patients. 10, 11 Moreover, stimulated IL-1β in SARS-CoV-2 infection was proposed to mediate lung and systemic inflammation, fever, and fibrosis. 12 Since cytokine storm is believed to be central to pulmonary immunopathology in SARS-CoV-2 infection, several studies have SHAFIEK ET AL. | 3925 focused on cytokine milieu and in particular IL-6 and IL-1β as potential blocking targets to calm the inflammatory storm. [10] [11] [12] [13] [14] Given the sparse data on the cytokine profile in pediatric COVID-19 ,   we investigated serum levels of a panel of key cytokines in children and   adolescents with COVID-19 pneumonia with a primary focus on "cytokine storm" cytokines such as IL-1β, IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ, TNF-α, and two chemokines interferon-inducible protein-10 (IP-10) and IL-8. We also studied whether these cytokines could be potential markers for illness severity in COVID-19 pneumonia. with ARF requiring mechanical ventilation (partial arterial oxygen pressure/fraction of inspired oxygen [PaO 2 /FiO 2 ] ratio < 300 despite oxygen therapy), shock, or organ failure.

Patients were further divided into two groups: Group 1 included 68 patients who had a moderate clinical type and Group 2 in which 18 cases had severe COVID-19 pneumonia and six were critical cases. No asymptomatic or mild cases were seen. Patients were admitted 24-48 h from onset of fever and cough and did not receive any treatment before enrollment in this study. For all patients, Chest X-rays and computed tomography (CT) images at the time of diagnosis were evaluated by an experienced emergency radiologist (SFO) who was blinded to the patients' clinical examination and lab results.

Typical CT features for COVID-19 were bilateral and multilobular ground-glass opacities mainly located in the lower lobes, consolidation with reverse halo sign, pleural thickening, pleural effusion, crazy paving pattern, interlobular septal thickening, and vacuolar sign. 17,18

Patients with primary or acquired immunodeficiency; malignancy; congenital heart disease (CHD); autoimmune disorders; or any chronic debilitating disease were excluded.

The control population comprised one hundred healthy children and adolescents, of matched age and gender; while attending for a routine checkup at outpatient clinics of the study hospitals (all were tested negative for SARS-CoV-2 by RT-PCR and without a previous history or diagnosis of lower respiratory tract infection).

For all subjects, nasal or pharyngeal swab, sputum sample, BALF, and/or tracheal aspirate were obtained. The presence of SARS-CoV-2 in respiratory fluid specimens was detected by rRT-PCR method using the forward primer 5′-ACTTCTTTTTCTTGCTTTCGTGGT-3′; reverse primer 5′-GCAGCAGTACGCACACAATC-3′; and the probe 5′CY5-CTAGTTACACTAGCCATCCTTACTGC-3′BHQ1 as previously described. 19 Respiratory fluid specimens from patients were cultured and screened for common bacterial or viral respiratory pathogen using the BioFIRE ® FilmARRAY ® Pneumoniaplus Panel-Multiplex PCR system (bioMerieux). were analyzed in the clinical laboratory at each study center on admission. Leucopenia and/or lymphopenia were determined according to age groups. 20 Chest tube inserted in the sixth intercostal space between the mid and posterior axillary line for cases with pleural effusion and/or empyema. An expert cardiothoracic surgeon (AIB) managed complicated cases.

For all subjects, we measured serum concentrations of 10 cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, IFN-γ, TNF Luminex 100/200 reader) using flow cytometry as previously described. 21 The assay sensitivity were as follows: 15 pg/ml for IL-1Β; 0.2 pg/ml for IL-2; 3 pg/ml for IL-6, IL-8; 5 pg/ml for IL-4, IL-10, IFNγ; 10 pg/ml for IL-17; 3.7 pg/ml for TNF-α, and 2.8 pg/ml for IP-10.

Statistical analyses were performed using IBM SPSS Statistics, version 23 for Windows. Categorical variables were compared by χ 2 test; meanwhile continuous parameters were compared using Student's t-

Mann-Whitney U test for nonparametric variables. To evaluate the diagnostic value of studied cytokines as potential predictors for COVID-19 disease severity, Receiver Operating characteristic (ROC) curve analysis was used and the area under ROC curve (AUC) was estimated and interpreted as: AUC < 0.7(poor accuracy); AUC = 0.7-0.8 (fair); AUC = 0.8-0.9 (good); AUC = 0.9-1.0 (excellent). Boxplots were drawn to describe serum cytokine concentrations. Correlation between paired data was analyzed by the Spearman correlation coefficient. A p value of less than 0.05 was considered statistically significant.

The median age of patients diagnosed with COVID-19 pneumonia was 10.5 years (range: 8.6-17.8 years) and 58 (63%) of them were males. The healthy control subjects were well-matched for age 9.7 (8-18 years) pneumonia as compared to the healthy control group suggesting that a cytokine storm may occur following SARS-CoV-2 infection as previously reported in adult studies. 2, 18, 24, 25 In keeping with a recent meta-analysis, 26 When we next compared the cytokine profile of studied patients subgrouped according to disease severity, we found that among studied cytokines only IL-1β, IL-6, and IP-10 showed significant differences between moderate and severe groups denoting increased expression of the three markers along with COVID-19 severity.

Moreover, we found significant negative correlations between serum IL-6, IL-1β, and IP-10 levels and other laboratory/clinical parameters (lymphocyte count, total WBC count, and oxygen saturation); respectively in COVID-19 pneumonia patients.

These results are concordant with numerous studies which demonstrated that higher levels of early response pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α); results in what has been described as "cytokine storm," were consistently associated with more severe COVID-19 disease and worse outcome. 2, 9, [25] [26] [27] [28] Ng et al. 27 In accordance with our findings, Grifoni et al. 35 reported that serum IL-6 level over 25 pg/ml was an independent risk factor for severe COVID-19 and hospital mortality in an Italian cohort of 77 adult patients. The AUC for IL-6 as a predictor of severe COVID-19 was 0.75, while it was 0.80 for IL-6 as a predictor of the combined endpoint. The authors concluded that IL-6 levels at hospital admission seem to be the best prognosticator for negative outcomes in COVID-19. 35 Similar study by Gao et al. 36 identified an optimal threshold of 24.3 pg/ml of IL-6 combined with D-Dimer for early prediction of severe COVID-19 cases in a Chinese cohort of 43 cases.

A recent meta-analysis involved nine studies confirmed that mean serum level of IL-6 was more than three-fold higher in complicated COVID-19 cases and was also associated with in-hospital mortality risk. 37 In another German cohort, IL-6 levels of more than 80 pg/ml were associated with a 22 times more need for mechanical ventilation. 38 Our findings also resonate with Yang et al. 39 Together with our findings, it is plausible to speculate that the three cytokines; IL-6, IL-1β, and IP-10 serum levels could be potential biomarkers for early detection of disease progression and severity in pediatric patients with COVID-19 pneumonia.

In SARS-CoV-2 experimental models, inhibition of nuclear factor kappa-B; a key transcription factor of IL-6, increased animal survival after a marked reduction in IL-6 levels. 43 

Our study shows that pediatric patients with COVID-19 pneumonia have markedly elevated serum IL-1β, IL-6, IL-8, IL-10, IL-17, TNF-α, and IP-10 levels at the initial phase of the illness indicating a cytokine storm following SARS-CoV-2 infection. Moreover, serum IL-6, IL-1β, and IP-10 concentrations were independent predictors for severe and critical COVID-19 pneumonia.

Finally, knowing the cytokine profile could help clinicians identifying potential targets in the cytokine milieu and inform the selection of candidate immunotherapy for robust evaluation against defined COVID-19 outcomes in future clinical trials setting.

No funds were available for the current research.

The authors declare that there are no conflict of interests. 

Hani A. Elmikaty: data curation (equal); formal analysis (equal); methodology (equal)

Lamya M. Ibrahim: data curation (equal); investigation (lead); methodology (lead); validation (equal); visualization (equal)

methodology (lead); supervision (equal); writing original draft (equal)

Rehab M Nabil: investigation (equal); methodology (lead); software (lead)

Ibrahim: investigation (lead); methodology (lead); resources (equal); supervision (equal)

visualization (supporting)

Salem: resources (equal); software (equal); supervision (equal); validation (equal); writing review & editing (equal). Ahmed A. M. Moustafa: data curation (equal); resources (lead)

visualization (equal). Naglaa A. Elshehawy: investigation (supporting)

Heba H. Eltrawy: conceptualization (lead); data curation (equal); methodology (equal); resources (supporting); validation (lead). Sherif F. Osman: investigation (lead); resources (equal); software (equal); validation (equal). Rania A. Fouad: investigation (lead); methodology (equal); resources (equal); validation (lead)

Mohamed Y. Mohamed: data curation (equal); formal analysis (equal); methodology (equal); resources (equal). Yousif M. Yousif: writing review & editing (lead). Aly A. Yousef: project administration (lead); software (supporting)

writing original draft (lead). Mohamed A. Arafa: conceptualization (equal)

data curation (equal); methodology (equal); supervision (equal)

DATA AVAILABILITY STATEMENT REFERENCES 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Cytokine synergy: an underappreciated contributor to innate anti-viral immunity

Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease

Molecular immune pathogenesis and diagnosis of COVID-19

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Interleukin-6 as a potential biomarker of COVID-19 progression

Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019

Mast cells contribute to coronavirus-induced inflammation: new antiinflammatory strategy

Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Updated diagnosis, treatment and prevention of COVID-19 in children: experts' consensus statement (condensed version of the second edition)

Diagnosis and treatment recommendation for pediatric coronavirus disease-19

COVID-19 pneumonia: a review of typical CT findings and differential diagnosis

Features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China

Novel coronavirus from patients with pneumonia in China

Lanzkowsky's Manual of Pediatric Hematology and Oncology

IP-10 is an early diagnostic marker for identification of late-onset bacterial infection in preterm infants

Thrombosis as an intravascular effector of innate immunity

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19

Cytokine storms: understanding COVID-19

Cytokine storm intervention in the early stages of COVID-19 pneumonia

Clinical manifestations of children with COVID-19: a systematic review

Inflammatory cytokine profile in children with severe acute respiratory syndrome

Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study

Interleukin-6 levels in children developing SARS-CoV-2 infection

Reduced inflammatory responses to SARS-CoV-2 infection in children presenting to hospital with COVID-19 in China

Expression of elevated levels of proinflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS

Role of interleukin 1 in the activation of T lymphocytes

Transcription and translation of proinflammatory cytokines following JHMV infection

IL-6 as a keystone cytokine in health and disease

Interleukin-6 as prognosticator in patients with COVID-19

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19

Elevated interleukin-6 and severe COVID-19: a meta-analysis

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

2019-novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury

IP-10 in autoimmune thyroiditis

CXCL10-CXCR3 enhances the development of neutrophil-mediated fulminant lung injury of viral and nonviral origin

Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival

National Health Commission of People's Republic of China

Cytokine profile in Egyptian children and adolescents with COVID-19 pneumonia: A multicenter study

Author elects to not share data due to privacy and ethical.

https://orcid.org/0000-0003-2206-9423